A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Cemiplimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 01 Nov 2018 Planned End Date changed from 6 Sep 2021 to 20 Sep 2022.
- 01 Nov 2018 Planned primary completion date changed from 6 Sep 2021 to 20 Sep 2022.
- 14 May 2018 Planned End Date changed from 1 Nov 2021 to 6 Sep 2021.